Compare AdaptHealth Corp (AHCO) vs Ambarella Inc (AMBA) Price & Performance

AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.

The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.

Ambarella (AMBA) trades at $79.73, up 1.75% with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a significant $800M+ long-term edge AI agreement with Hanwha. Revenue grew 16.9% year-over-year in Q1 2027 to $100.4M, though the company remains unprofitable with a -17.18% net income margin. Analyst sentiment is strongly positive with 58% buy ratings and a $108.67 consensus price target representing 36% upside potential.

Ambarella presents a compelling growth story in edge AI with strong analyst support and recent business momentum, but faces execution risks in transitioning to profitability. The stock's current valuation at 8.47x sales appears justified given the company's positioning in the rapidly expanding physical AI market, though investors should monitor progress toward sustainable profitability and competitive pressures in the semiconductor space.